A guidance raise that didn't move the needle
Novo narrowed its projected annual decline from 8% to 3% at the midpoint on August 4. That's a meaningful improvement, but investors weren't impressed. The stock fell anyway, a sign that the market is focused on the competitive pressure from Lilly rather than the better-than-expected outlook.
" Translation: "Kenaikan panduan yang tidak memberi kesan
Novo mengecilkan jangkaan penurunan tahunan daripada 8% kepada 3% pada titik tengah pada 4 Ogos. Itu adalah peningkatan yang bermakna, tetapi pelabur tidak terkesan. Saham tetap jatuh, tanda bahawa pasaran memberi tumpuan kepada tekanan persaingan daripada Lilly daripada prospek yang lebih baik daripada jangkaan.
" We need to translate "didn't move the needle" -> "tidak memberi kesan" or "tidak mengubah keadaan". "narrowed its projected annual decline" -> "mengecilkan jangkaan penurunan tahunan" (narrowed the expected annual decline). "at the midpoint" -> "pada titik tengah" (maybe "pada pertengahan" but "midpoint" is fine). "meaningful improvement" -> "peningkatan yang bermakna". "weren't impressed" -> "tidak terkesan". "competitive pressure" -> "tekanan persaingan". "better-than-expected outlook" -> "prospek yang lebih baik daripada jangkaan". Third paragraph: "The price cut trade-off
Novo slashed prices on Ozempic and Wegovy last year to widen patient access. The move was meant to boost volume, but that volume hasn't caught up yet to offset the cuts. That's why the guidance raise is modest, and why the company is still projecting a decline in sales for the year.
" Translation: "Keseimbangan pemotongan harga
Novo memotong harga Ozempic dan Wegovy tahun lepas untuk meluaskan akses pesakit. Langkah itu bertujuan untuk meningkatkan volum, tetapi volum itu belum mengejar untuk mengimbangi pemotongan tersebut. Itulah sebabnya kenaikan panduan adalah sederhana, dan mengapa syarikat masih menjangkakan penurunan jualan untuk tahun ini.
" "trade-off" -> "keseimbangan" or "pertukaran" but "trade-off" is often left as is. Better to use "pertukaran" or "kompromi". Actually "trade-off" means a balance between two things, so "keseimbangan" works. "slashed prices" -> "memotong harga" (cut prices). "widen patient access" -> "meluaskan akses pesakit". "boost volume" -> "meningkatkan volum". "caught up" -> "mengejar" (catch up). "offset" -> "mengimbangi". "modest" -> "sederhana". "projecting a decline" -> "menjangkakan penurunan". Fourth paragraph: "Oral Wegovy's fast start
The pill version of Wegovy launched in January and quickly became one of the fastest-selling drugs in pharmaceutical history. Doctors have written more than 5 million prescriptions, and 1.5 million patients now take it worldwide. Doustdar called it the best product launch in pharmaceutical history. The pill cuts weight by 17% in Novo's own trials, against 12% for Lilly's rival pill, though the two drugs haven't faced off head-to-head.
" Translation: "Permulaan pantas Wegovy oral
Versi pil Wegovy dilancarkan pada Januari dan dengan cepat menjadi salah satu ubat paling laris dalam sejarah farmaseutikal. Doktor telah menulis lebih daripada 5 juta preskripsi, dan 1.5 juta pesakit kini mengambilnya di seluruh dunia. Doustdar menyebutnya sebagai pelancaran produk terbaik dalam sejarah farmaseutikal. Pil itu mengurangkan berat badan sebanyak 17% dalam ujian Novo sendiri, berbanding 12% untuk pil saingan Lilly, walaupun kedua-dua ubat itu tidak pernah berhadapan secara langsung.
" "fast start" -> "permulaan pantas". "pill version" -> "versi pil". "launched" -> "dilancarkan". "fastest-selling" -> "paling laris" (best-selling). "prescriptions" -> "preskripsi". "patients" -> "pesakit". "called it" -> "menyebutnya". "best product launch" -> "pelancaran produk terbaik". "cuts weight by 17%" -> "mengurangkan berat badan sebanyak 17%". "in Novo's own trials" -> "dalam ujian Novo sendiri". "against 12% for Lilly's rival pill" -> "berbanding 12% untuk pil saingan Lilly". "faced off head-to-head" -> "berhadapan secara langsung" (or "bertemu secara langsung"). Fifth paragraph: "The Lilly rivalry
Doustdar acknowledged that Lilly is more diversified. Novo's obesity and diabetes drugs now make up around 90% of its business, compared to about 60% at Lilly. That concentration makes Novo more exposed to the GLP-1 market's ups and downs. Novo is also suing Lilly over advertising claims that compare an older, lower-dose version of Wegovy. Novo's newer high-dose formulation matches Lilly's efficacy, according to Doustdar.
" Translation: "Persaingan dengan Lilly
Doustdar mengakui bahawa Lilly lebih pelbagai. Ubat obesiti dan diabetes Novo kini membentuk sekitar 90% daripada perniagaannya, berbanding kira-kira 60% di Lilly. Ke
